SciTech FAQ

Frequently Asked Questions

Who is SciTech Development?


SciTech is an emerging pharmaceutical company that is developing new cancer drugs.


Where is SciTech located?


SciTech is headquartered in the Metro Detroit Area in Michigan with laboratories at the LifeBridge Health BioIncubator at the Sinai Hospital in Baltimore, Maryland.


What types of cancer is SciTech targeting?


T-cell non-Hodgkin's lymphoma (T-cell NHL), small cell lung cancer (SCLC), metastatic breast cancer (MBC), neuroblastoma, T-ALL (acute lymphoblastic leukemia), breast, cervical, colorectal, head & neck, leukemia, ovarian, kidney, pancreatic and prostate cancers.  


Why so many cancer targets?


These are all cancer indications in which our active pharmaceutical ingredient (API) fenretinide has shown promising results in pre-clinical or clinical studies.


What is SciTech's cancer drug treatment?


SciTech’s intravenous drug is ST-001 nanoFenretinide and consists of nanoparticle sized fenretinide in a phospholipid matrix. Fenretinide is well-known and has been studied in both humans and animal models.


If fenretinide is well known why hasn’t it been commercialized already?


The problem with fenretinide has been its poor bioavailability (limited water solubility) which has impeded its development as a drug. SciTech has overcome this limitation with its patented nanoFenretinide technology.


What are SciTech's product sales and revenue?


SciTech does not have any products on the market or any commercial revenue yet. We are currently seeking investors and partners to bring our nanoFenretinide technology to market.


What type of investors and partners is SciTech looking for?


We are currently closing on a $1MM Convertible Note Round (CNR) of funding and are seeking a $15MM Series A equity investment to bring our lead drug product ST-001 nanoFenretinide to market for the treatment of T-cell NHL and small cell lung cancer (SCLC). We are seeking partners with the resources to manufacture, distribute and sell our drug products.


Does SciTech have FDA drug approval?


No. The FDA has recently approved SciTech’s IND application for ST-001 nanoFenretinide treatment of T-cell NHL. The FDA approved IND provides clearance for ST-001 nanoFenretinide to enter the clinic.  The FDA has already granted Orphan Drug Designation for ST-001 nanoFenretinide treatment of T-cell NHL.


Is SciTech’s technology patented?


Yes. SciTech has patents issued in the US, EU, Canada, Australia & New Zealand covering ST-001 nanoFenretinide composition, ST-001 drug combinations, and the delivery platform for limited water-soluble drugs (patent expiration June 2030). SciTech has recently filed a provisional patent application titled "Use of Fenretinide Nanoparticles for Immunotherapeutic Cancer Treatment".


Who can I contact about investing in SciTech or partnering with SciTech?


Contact Earle Holsapple | (313) 263-4887 |

What is fenretinide?


Fenretinide is a synthetic derivative of naturally occurring retinol (vitamin A) & retinoic acid and is in the retinoid class of chemical compounds.

What are the physical properties of fenretinide?


Fenretinide is a small organic molecule comprised of carbon, hydrogen, oxygen and nitrogen with a molecular weight of 391.5 g/mol; it is a water insoluble (hydrophobic) orange yellow powder.

Does fenretinide have biological activity?


Yes. Clinical or pre-clinical studies support the use of fenretinide as a treatment in several types of cancer as well as in the treatment of cystic fibrosis, rheumatoid arthritis, macular degeneration and Stargardt disease.

Where does fenretinide come from?


Fenretinide is synthetic. It was first synthesized in the 1960s by Robert J. Gander at the Johnson & Johnson (J&J) pharmaceutical company for dermatological applications (including acne).

What is fenretinide's biological or drug mechanism of action (MOA)?


Fenretinide targets multiple MOAs which gives it a broad therapeutic reach. It is selectively cytotoxic and destroys cancer cells by inducing apoptosis (a form of programmed cell death). The drug also works by other, as of yet, unknown mechanism(s).

Are there any fenretinide drugs approved by the FDA?


No. Currently there are no fenretinide drug products on the market. The main problem with fenretinide has been its poor bioavailability or hydrophobicity (water insolubility) which has impeded its development as a drug. SciTech has overcome this limitation with its patented nanoFenretinide technology.

Who is SciTech?


SciTech Development is an emerging pharmaceutical company that is developing new cancer drugs including ST-001 nanoFenretinide. SciTech is currently seeking investors and partners to bring its fenretinide technology to market.

Who can I contact about partnering or investing in SciTech?


Contact Earle Holsapple | (313) 263-4887 |

What is nanoFenretinide?


NanoFenretinide is nanometer (nm) particle sizes of fenretinide; fenretinide is a well-known anti-cancer agent.

What is a nanometer (nm)?


A nanometer is a unit of length in the metric system, strictly speaking it is 1x10^-9 meters (or one billionth of a meter), about 1000 times smaller than the width of a human hair.

What is ST-001 nanoFenretinide?


ST-001 nanoFenretinide is SciTech's patented, nanoparticle fenretinide drug formulation in a phospholipid matrix (a carefully selected suite of phospholipids to enhance the drug bioavailability or water solubility).

What are phospholipids?


Phospholipids are a class of lipids (biological molecules) that contain a phosphate group in the molecule. Phospholipids are a major component of all cell membranes.

What are the particle sizes in ST-001 nanoFenretinide?


Generally, less than two hundred nanometers (<200 nm).

Why such small sizes for ST-001 nanoFenretinide?


Several reasons: (1) The small size allows the drug to be readily administered intravenously without causing any circulatory blockage, thereby allowing the drug to be easily distributed in the body; (2) The small size allows the drug product to be processed by sterile filtration, a process of removing microorganisms (e.g., bacteria) from a fluid stream without adversely affecting the drug product; and, (3) The small sized fenretinide combined with the phospholipids in the nanoFenretinide formulation forms a nano suspension in water (aqueous suspension) thereby increasing the drug's bioavailability.

What are the benefits ST-001 nanoFenretinide?


In addition to the benefits provided above, SciTech's proprietary nanoFenretinide technology allows for high drug loading (increased potency); enhanced bioavailability or increased water solubility of fenretinide and other hydrophobic drugs (water insoluble drugs); and, triglyceride free & oil free drug formulations.

How can I learn more?


Visit our website at

Who can I contact at SciTech?


For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | (313) 263-4887 |

Follow us on Google